
Opinion|Videos|May 28, 2024
CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
- What are the unmet needs?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
3
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
4
Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD
5











